HIV in Women
Methodology & AI Transparency ⓘ
HIV in Women Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is HIV? HIV stands for human immunodeficiency virus.
- 2 Real-world patient consensus: Clinical coding for HIV in Women uses ICD-10 L03.8 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Workup highlights for HIV in Women (L03.8): antimicrobial stewardship (narrow-spectrum in HIV in Women (L03.8: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Longitudinal HIV in Women monitoring tracks Complete Blood Count in HIV in Women (L03.8: (WBC & Differential)) toward WBC 4.0 – 10.0 x10^3/uL (L03.8).
Ask our AI Specialists anything about HIV in Women
What Is HIV in Women?
What is HIV? HIV stands for human immunodeficiency virus. It harms your immune system by destroying a type of white blood cell that helps your body fight infection. This puts you at risk for other infections and diseases. How does HIV spread? HIV can spread in different ways: By having unprotected vaginal or anal sex with a person who has HIV. "Unprotected" means not using condoms or medicine to treat or prevent HIV. This is the most common way it spreads. Anal sex is the riskiest type of sex for getting or spreading HIV. The rectum's lining is thin and may allow HIV to enter the body during anal sex.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of HIV in Women (L03.8) center on tissue neutrophil/lymphocyte recruitment [HIV in Women L03.8]. Cross-referenced with NIH MeSH (HIV Infections), targeted infections & antivirals interventions aim to normalize Complete Blood Count in HIV in Women (L03.8: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • During vaginal sex, HIV can enter the body through the delicate tissue that lines the vagina and cervix
- • Rarely, through oral sex with a person who has HIV
- • Presentation of HIV in Women (L03.8): regional lymph node in HIV in Women (L03.8: tenderness or acute)
- • Secondary HIV in Women clinical sign: acute fever, chills, in HIV in Women (L03.8: malaise, and myalgias)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
HIV in Women Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L03.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in HIV in Women (L03.8: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (L03.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in HIV in Women (L03.8: Procalcitonin) | Resolution to baseline (L03.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in HIV in Women (L03.8: Culture & Sensitivity) | Pathogen clearance / negative test (L03.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for HIV in Women
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dinoprostone Cervidil, Prepidil • RxCUI 597957 | Prostaglandin Analog | 93% | $1.6400 | $ 74.92 /mo |
| Lotronex (Alosetron Hydrochloride) Lotronex • RxCUI 261362 | Serotonin-3 Receptor Antagonist | 79% | $2.5631 | $ 30.28 /mo |
| Letrozole Femara • RxCUI 200064 | Aromatase Inhibitor | 84% | $0.1408 | $ 7.48 /mo |
| Norgestimate and Ethinyl Estradiol Tri-Linyah, Estarylla • RxCUI 240128 | FDA Prescription Therapeutic Agent | 78% | $0.1234 | $ 13.50 /mo |
| Levonorgestrel and Ethinyl Estradiol Vienva Tm, Altavera • RxCUI 722152 | Progestin | 93% | $0.1509 | $ 8.73 /mo |
| Levonorgestrel/Ethinyl Estradiol Twirla, Jolessa • RxCUI 2396242 | Progestin | 85% | $66.7058 | $ 6.73 /mo |
| Exemestane Aromasin • RxCUI 310261 | Aromatase Inhibitor | 84% | $0.5751 | $ 11.90 /mo |
| Alosetron Hydrochloride Lotronex • RxCUI 259306 | Serotonin-3 Receptor Antagonist | 81% | $1.9490 | $ 30.28 /mo |
| Oxytrol for Women (Oxybutynin) Oxytrol for Women • RxCUI 403799 | Cholinergic Muscarinic Antagonist | 86% | $2.7140 | $ 203.91 /mo |
| Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Tablets Xarah Fe • RxCUI 259176 | FDA Prescription Therapeutic Agent | 78% | $0.7339 | $ 38.22 /mo |
| Drospirenone and Ethinyl Estradiol Syeda, Vestura • RxCUI 284207 | FDA Prescription Therapeutic Agent | 80% | $0.1445 | $ 14.35 /mo |
| Norethindrone and Ethinyl Estradiol Tablet Rhuzdah • RxCUI 238015 | FDA Prescription Therapeutic Agent | 94% | $0.0849 | $ 11.94 /mo |
| Norethindrone Acetate/Ethinyl Estradiol Larin 1.5/30, Microgestin 1.5/30 • RxCUI 1359022 | Birth Control Agent | 84% | $0.3169 | $ 7.17 /mo |
| Vite20 (Miconazole Nitrate) Vite20 • RxCUI 998525 | Women's Health Agent | 88% | $0.4152 | $ 38.40 /mo |
| Doxorubicin Hydrochloride Doxil • RxCUI 1790095 | Anthracycline Topoisomerase Inhibitor | 75% | $2.0700 | $ 92.33 /mo |
| Levonorgestrel Tablet, 1.5 Mg Optionelle • RxCUI 483325 | Progestin | 83% | $6.6295 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (HIV in Women)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of sildenafil citrate on treatment of infertility in women with a thin: What a 1,452-Participant Study Found Sildenafil citrate is effective in improving endometrial thickness, the clinical pregnancy rate, and the biochemical pregnancy rate in women who have a thin endometrium. The Journal of international medical research • 2020-11-15 • Meta-Analysis | N = 1,452 | 99/100 | PMID 33176524 ↗ |
| New Insights on Metabolic and heart and blood vessel effects of TX-001HR in menopausal women with: What a 1,835-Participant Study Found One episode of deep venous thrombosis and three cases of heart and blood vessel disease were observed, similar to expected rates of these events in the general population. Climacteric : the journal of the International Menopause Society • 2019-12-15 • Randomized Controlled Trial | N = 1,835 | 96/100 | PMID 31364889 ↗ |
| New Insights on Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal: What a 16,071-Participant Study Found These results. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2021-07-15 • Phase III Randomized Trial | N = 16,071 | 96/100 | PMID 33724542 ↗ |
| New Insights on Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable: What a 1,022-Participant Study Found This pooled analysis demonstrated efficacy of fezolinetant vs. Current medical research and opinion • 2025-02-15 • Randomized Controlled Trial | N = 1,022 | 96/100 | PMID 40044127 ↗ |
| New Insights on Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response: What a 1,313-Participant Study Found The E-R results support the MOV dose of 800 mg twice daily to treat COVID-19. Clinical pharmacology and therapeutics • 2023-06-15 • Phase III Randomized Trial | N = 1,313 | 96/100 | PMID 37017631 ↗ |
HIV in Women Patient Community & “People Like Me” Threads
Filter HIV in Women community threads and patient logs by age, biological sex, dosage, and treatment duration.